Acadia Pharmaceuticals (ACAD) Common Equity (2010 - 2026)

Acadia Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Common Equity rose 63.1% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 63.1% YoY), while the FY2025 annual figure was $1.2 billion, up 67.49% from the prior year.
• Common Equity was $1.2 billion for Q1 2026 at Acadia Pharmaceuticals, up from $1.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.2 billion in Q1 2026 to a low of $362.2 million in Q3 2023.
• Historically, Common Equity has averaged $620.0 million across 5 years, with a median of $464.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity decreased 25.97% in 2022, then soared 69.72% in 2024.
• A 5-year view of Common Equity shows it stood at $400.4 million in 2022, then rose by 7.83% to $431.8 million in 2023, then jumped by 69.72% to $732.8 million in 2024, then soared by 67.49% to $1.2 billion in 2025, then rose by 1.68% to $1.2 billion in 2026.
• The last three Common Equity figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $917.3 million (Q3 2025), per Business Quant data.